Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.46
CERS's Cash to Debt is ranked lower than
65% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. CERS: 4.46 )
Ranked among companies with meaningful Cash to Debt only.
CERS' s Cash to Debt Range Over the Past 10 Years
Min: 0.62  Med: 83.75 Max: 14206.57
Current: 4.46
0.62
14206.57
Equity to Asset 0.62
CERS's Equity to Asset is ranked lower than
57% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CERS: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
CERS' s Equity to Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.67 Max: 0.9
Current: 0.62
0.06
0.9
F-Score: 4
Z-Score: 1.15
M-Score: -2.99
WACC vs ROIC
11.82%
-904.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -182.93
CERS's Operating margin (%) is ranked lower than
58% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. CERS: -182.93 )
Ranked among companies with meaningful Operating margin (%) only.
CERS' s Operating margin (%) Range Over the Past 10 Years
Min: -390.85  Med: -96.79 Max: -7.75
Current: -182.93
-390.85
-7.75
Net-margin (%) -189.29
CERS's Net-margin (%) is ranked lower than
58% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. CERS: -189.29 )
Ranked among companies with meaningful Net-margin (%) only.
CERS' s Net-margin (%) Range Over the Past 10 Years
Min: -410.21  Med: -107.85 Max: -15.77
Current: -189.29
-410.21
-15.77
ROE (%) -71.31
CERS's ROE (%) is ranked lower than
73% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CERS: -71.31 )
Ranked among companies with meaningful ROE (%) only.
CERS' s ROE (%) Range Over the Past 10 Years
Min: -140.02  Med: -81.39 Max: -7.02
Current: -71.31
-140.02
-7.02
ROA (%) -48.53
CERS's ROA (%) is ranked lower than
68% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. CERS: -48.53 )
Ranked among companies with meaningful ROA (%) only.
CERS' s ROA (%) Range Over the Past 10 Years
Min: -65.51  Med: -46.6 Max: -5.48
Current: -48.53
-65.51
-5.48
ROC (Joel Greenblatt) (%) -911.77
CERS's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. CERS: -911.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CERS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2927.5  Med: -852.6 Max: -164.15
Current: -911.77
-2927.5
-164.15
Revenue Growth (3Y)(%) -19.10
CERS's Revenue Growth (3Y)(%) is ranked lower than
72% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CERS: -19.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CERS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.5  Med: 4.3 Max: 52.4
Current: -19.1
-44.5
52.4
EBITDA Growth (3Y)(%) 30.40
CERS's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. CERS: 30.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CERS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.8  Med: 10.1 Max: 127.1
Current: 30.4
-52.8
127.1
EPS Growth (3Y)(%) 22.70
CERS's EPS Growth (3Y)(%) is ranked higher than
78% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CERS: 22.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CERS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: 2.65 Max: 22.7
Current: 22.7
-30.1
22.7
» CERS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CERS Guru Trades in Q3 2015

Ron Baron 175,000 sh (+16.67%)
PRIMECAP Management 7,500,000 sh (+1.35%)
Chuck Royce 2,245,405 sh (-19.84%)
» More
Q4 2015

CERS Guru Trades in Q4 2015

PRIMECAP Management 7,500,000 sh (unchged)
Ron Baron 110,000 sh (-37.14%)
Chuck Royce 1,199,100 sh (-46.60%)
» More
Q1 2016

CERS Guru Trades in Q1 2016

Jim Simons 18,600 sh (New)
PRIMECAP Management 7,800,000 sh (+4.00%)
Ron Baron 63,000 sh (-42.73%)
Chuck Royce 268,000 sh (-77.65%)
» More
Q2 2016

CERS Guru Trades in Q2 2016

Ron Baron 81,000 sh (+28.57%)
Jim Simons 21,400 sh (+15.05%)
PRIMECAP Management 7,800,000 sh (unchged)
Chuck Royce 248,000 sh (-7.46%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ZIOP, NAS:GBT, OTCPK:GNFTF, OTCPK:PHMMF, NAS:ANIK, NAS:EDIT, NAS:VNDA, NAS:ANIP, OTCPK:BPMUF, NAS:INO, NAS:NK, NAS:NTLA, OTCPK:IPHYF, NAS:DVAX, NAS:AMRI, NAS:BPMC, NAS:AIMT, NAS:RPTP, NAS:MACK, NAS:PACB » details
Traded in other countries:CU2.Germany,
Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 12 issued or allowed United States patents and approximately 87 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations' blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.

Guru Investment Theses on Cerus Corp

Baron Funds Comments on Cerus Corp - Feb 25, 2016

Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Cerus Corp

Baron Funds Comments on Cerus Corp Guru stock highlight
Cerus Corporation (NASDAQ:CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect these markets, which are currently worth about $800 million (for platelets and plasma), could grow to over $3 billion when PI is extended to red blood cell inactivation over the next three to four years. Read more...

Ratios

vs
industry
vs
history
P/B 9.28
CERS's P/B is ranked lower than
81% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CERS: 9.28 )
Ranked among companies with meaningful P/B only.
CERS' s P/B Range Over the Past 10 Years
Min: 0.81  Med: 6.22 Max: 55
Current: 9.28
0.81
55
P/S 19.29
CERS's P/S is ranked lower than
63% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. CERS: 19.29 )
Ranked among companies with meaningful P/S only.
CERS' s P/S Range Over the Past 10 Years
Min: 1.22  Med: 6.95 Max: 21.11
Current: 19.29
1.22
21.11
EV-to-EBIT -9.94
CERS's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. CERS: -9.94 )
Ranked among companies with meaningful EV-to-EBIT only.
CERS' s EV-to-EBIT Range Over the Past 10 Years
Min: -55.3  Med: -7.9 Max: -0.2
Current: -9.94
-55.3
-0.2
EV-to-EBITDA -10.23
CERS's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. CERS: -10.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
CERS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.6  Med: -8.3 Max: -0.2
Current: -10.23
-79.6
-0.2
Current Ratio 4.36
CERS's Current Ratio is ranked higher than
51% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. CERS: 4.36 )
Ranked among companies with meaningful Current Ratio only.
CERS' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 4 Max: 9.96
Current: 4.36
1.03
9.96
Quick Ratio 3.89
CERS's Quick Ratio is ranked lower than
51% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CERS: 3.89 )
Ranked among companies with meaningful Quick Ratio only.
CERS' s Quick Ratio Range Over the Past 10 Years
Min: 1.03  Med: 3.77 Max: 9.96
Current: 3.89
1.03
9.96
Days Inventory 211.40
CERS's Days Inventory is ranked lower than
70% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.14 vs. CERS: 211.40 )
Ranked among companies with meaningful Days Inventory only.
CERS' s Days Inventory Range Over the Past 10 Years
Min: 122.1  Med: 212.05 Max: 343.01
Current: 211.4
122.1
343.01
Days Sales Outstanding 54.34
CERS's Days Sales Outstanding is ranked higher than
56% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. CERS: 54.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.2  Med: 68.14 Max: 256.86
Current: 54.34
44.2
256.86
Days Payable 125.20
CERS's Days Payable is ranked higher than
74% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.75 vs. CERS: 125.20 )
Ranked among companies with meaningful Days Payable only.
CERS' s Days Payable Range Over the Past 10 Years
Min: 81.15  Med: 127.78 Max: 1578.67
Current: 125.2
81.15
1578.67

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.80
CERS's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CERS: -20.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CERS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.8  Med: -13.5 Max: -6.8
Current: -20.8
-20.8
-6.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.07
CERS's Price/Net Cash is ranked lower than
77% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CERS: 16.07 )
Ranked among companies with meaningful Price/Net Cash only.
CERS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.88  Med: 7 Max: 103.13
Current: 16.07
1.88
103.13
Price/Net Current Asset Value 10.38
CERS's Price/Net Current Asset Value is ranked lower than
70% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CERS: 10.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CERS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.17  Med: 7.28 Max: 317.86
Current: 10.38
1.17
317.86
Price/Tangible Book 9.56
CERS's Price/Tangible Book is ranked lower than
76% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. CERS: 9.56 )
Ranked among companies with meaningful Price/Tangible Book only.
CERS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.92  Med: 6.82 Max: 250
Current: 9.56
0.92
250
Price/Median PS Value 2.78
CERS's Price/Median PS Value is ranked lower than
87% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CERS: 2.78 )
Ranked among companies with meaningful Price/Median PS Value only.
CERS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.32 Max: 74.5
Current: 2.78
0.2
74.5
Earnings Yield (Greenblatt) (%) -10.10
CERS's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CERS: -10.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CERS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.76  Med: 295.1 Max: 2848.7
Current: -10.1
-18.76
2848.7

More Statistics

Revenue (TTM) (Mil) $34.58
EPS (TTM) $ -0.67
Beta1.37
Short Percentage of Float18.56%
52-Week Range $4.27 - 7.64
Shares Outstanding (Mil)102.71

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 58 84
EPS ($) -0.68 -0.52 -0.36
EPS w/o NRI ($) -0.68 -0.52 -0.36
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CERS

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Cerus Corp Feb 25 2016 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
UPDATE 4-FDA recommends Zika testing for all blood donated in U.S. Aug 27 2016
ETF’s with exposure to Cerus Corp. : August 26, 2016 Aug 26 2016
CERUS CORP Financials Aug 16 2016
Which Stocks Are Impacted by the Rio Olympics? Aug 13 2016
Obama Moves Money Around To Keep Zika Research Going Amid Lack Of Congressional Funds Allocation Aug 12 2016
ETF’s with exposure to Cerus Corp. : August 11, 2016 Aug 11 2016
Cerus Corp. :CERS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer Aug 09 2016
Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer Aug 09 2016
Edited Transcript of CERS earnings conference call or presentation 4-Aug-16 8:15pm GMT Aug 08 2016
Watch these biotechs as the Zika virus moves to the U.S. Aug 06 2016
CERUS CORP Files SEC form 10-Q, Quarterly Report Aug 05 2016
Cerus reports 2Q loss Aug 04 2016
Cerus reports 2Q loss Aug 04 2016
Cerus Corporation Reports Second Quarter 2016 Results Aug 04 2016
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 04 2016
Cerus Corporation Reports Second Quarter 2016 Results Aug 04 2016
Q2 2016 Cerus Corp Earnings Release - After Market Close Aug 04 2016
Cerus (CERS) in Focus: Stock Moves 6% Higher in Session Aug 01 2016
Friday's Zika Reports Explained: Winners And Losers Jul 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)